drugset / Trial / NCT05528588

Furoscix in Heart Failure Patients With Diuretic Resistance

NCT05528588

RandomizedFactorialOpen-labelTreatment

Summary

This will be a randomized, open-label pilot study of 70 patients with and without diuretic resistance who were recently admitted and discharged for acute decompensated heart failure with and oral diuretic regimen testing whether Furoscix is more effective at achieving post-discharge outpatient diuresis than standard of care. Diuretic resistance will be identified using the BAN-ADHF (BUN, creAtinine, NP-levels, Age, Diabetes and DBP, HF hospitalization, and atrial Fibrillation) score which has been integrated into the electronic health record. The score is integer-based with a score of ≥ 12 indicating diuretic resistance with high likelihood of poor outcomes. The primary outcome is diuretic efficacy as measured by volume of urine produced 8 hours after treatment and urine sodium levels (assessed hourly or per urination episode within 8 hours of treatment).

Timeline

Start
2023-06-02
Primary completion
2024-04-22
Completion
2024-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 80 mg Subcutaneous

Indications